| Pair Name | Ginsenoside, Regorafenib | ||
| Phytochemical Name | Ginsenoside (PubChem CID: 3086007 ) | ||
| Anticancer drug Name | Regorafenib (PubChem CID: 11167602 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Ginsenoside, Regorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BIRC5 | hsa332 |
| Up-regulation | Expression | CASP3 | hsa836 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| Result | The findings in this study offered a theoretical insight into clinical use of regorafenib and ginsenoside for treatment of liver cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression. Clin Transl Oncol. 2020 Sep;22(9):1491-1498. doi: 10.1007/s12094-019-02283-9. | Click |
